Pfizer’s Braftovi+Mektovi shows sustained long-term survival in patients with advanced lung cancer

Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population

Bajaj Healthcare posts Q2 FY26 PAT at Rs. 11.10 Cr

Bajaj Healthcare has reported total income of Rs. 149.56 crore during the period ended September 30, 2025

TTK Healthcare reports Q2 FY26 net profit at Rs. 20.38 Cr

TTK Healthcare has reported total income of Rs. 222.58 crore during the period ended September 30, 2025

Qure.ai receives regulatory clearance for AI tool for early detection of TB in children below 3 years

Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis

RPG Life Sciences posts Q2 FY26 PAT at Rs. 36.85 Cr

RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025

Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC

Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab

FDA approves Tezspire for chronic rhinosinusitis with nasal polyps

Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation

Roquette opens health and pharma solutions innovation center in Brazil

This new facility strengthens Latin America as a collaborative hub

FDA approves Alembic’s Triamcinolone Acetonide injectable suspension USP, 40 mg/mL

Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions

Cupid achieves CE (EU IVDR) certification for pregnancy and syphilis test kits